BLTE vs. MNKD, XNCR, MIRM, ABCL, ELVN, PRTA, GYRE, VRNA, COLL, and GMTX
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include MannKind (MNKD), Xencor (XNCR), Mirum Pharmaceuticals (MIRM), AbCellera Biologics (ABCL), Enliven Therapeutics (ELVN), Prothena (PRTA), Gyre Therapeutics (GYRE), Verona Pharma (VRNA), Collegium Pharmaceutical (COLL), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical preparations" industry.
Belite Bio (NASDAQ:BLTE) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
MannKind has a net margin of 3.78% compared to Belite Bio's net margin of 0.00%. MannKind's return on equity of -3.35% beat Belite Bio's return on equity.
MannKind received 550 more outperform votes than Belite Bio when rated by MarketBeat users. However, 95.83% of users gave Belite Bio an outperform vote while only 59.87% of users gave MannKind an outperform vote.
MannKind has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.
In the previous week, Belite Bio had 20 more articles in the media than MannKind. MarketBeat recorded 32 mentions for Belite Bio and 12 mentions for MannKind. MannKind's average media sentiment score of 0.41 beat Belite Bio's score of 0.18 indicating that MannKind is being referred to more favorably in the news media.
Belite Bio currently has a consensus target price of $44.83, indicating a potential downside of 0.30%. MannKind has a consensus target price of $8.00, indicating a potential upside of 74.29%. Given MannKind's higher probable upside, analysts clearly believe MannKind is more favorable than Belite Bio.
0.5% of Belite Bio shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 3.0% of MannKind shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Belite Bio has a beta of -1.52, meaning that its stock price is 252% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.
Summary
MannKind beats Belite Bio on 12 of the 16 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
